MRNA vs NKTR
MRNA: Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales. NKTR: A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | MRNA | NKTR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.07 | $69.32 | |
| Market cap as of 2026-07-23 | $22.9B | $2.4B | |
| Net margin as of 2026-07-23 | -143.6% | -280.8% | MRNA higher |
| Gross margin as of 2026-07-23 | +35.0% | +100.0% | NKTR higher |
| Operating margin as of 2026-07-23 | -153.3% | -242.0% | MRNA higher |
| ROE as of 2026-07-23 | -36.7% | -45.8% | MRNA higher |
| ROA as of 2026-07-23 | -26.6% | -40.3% | MRNA higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.10 | MRNA lower |
| Revenue growth (YoY) as of 2026-07-23 | -30.0% | -36.2% | MRNA higher |
| Revenue CAGR (3y) SEC XBRL | -53.4% | -15.7% | NKTR higher |
| Beta as of 2026-07-23 | 0.88 | 1.13 | |
| 1-year return as of 2026-07-22 close | +77.4% | +183.2% | NKTR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.